热门资讯> 正文

Monopar Therapeutics GAAP每股收益为-0.61美元，低于0.16美元

2026-03-28 04:47

Monopar Therapeutics(MNPR) 0

Monopar Therapeutics press release (MNPR): Q4 GAAP EPS of -$0.61 misses by $0.16.
Cash, cash equivalents and short-term investments as of December 31, 2025, were $140.4 million.

More on Monopar Therapeutics

Seeking Alpha’s Quant Rating on Monopar Therapeutics
Historical earnings data for Monopar Therapeutics
Financial information for Monopar Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。